<DOC>
	<DOCNO>NCT00406029</DOCNO>
	<brief_summary>The purpose study assess efficacy safety range dose SCH 420814 ( preladenant ) use together stable dose L-dopa/dopa decarboxylase inhibitor treat Parkinson 's disease . In study , compare 3 dos ( 1 mg , 2 mg , 5 mg take twice day ) preladenant placebo ( sugar pill ) . Following Interim Analysis ( temporary hold new enrollment-ongoing subject continue treatment ) review drug safety , new dose group 10 mg ( take twice day ) may add . Approximately 160 participant randomize study approximately 22 study center worldwide first part study . Following Interim Analysis , 40 new participant may add , total 200 participant . The study double blind , mean neither study doctor know whether receive study medication placebo .</brief_summary>
	<brief_title>Dyskinesia Parkinson 's Disease ( Study P04501 )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Participants must 30 year age , either sex race , diagnosis moderate severe idiopathic Parkinson 's disease least 5 year . Women childbearing potential must negative serum pregnancy test Visit 2 ( Week 1 ) . If participant postmenopausal ( surgically induce ) , must postmenopausal history least 2 year study entry . If , proper birth control must use . Note : Acceptable method birth control include oral injectable hormonal contraceptive , medically prescribe intrauterine device ( IUD ) , doublebarrier method ( eg , condom combination spermicide ) . Bilateral tubal ligation acceptable method birth control study . Participants ' clinical laboratory test ( complete blood count [ CBC ] , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator/sponsor . Participants form druginduced atypical parkinsonism , cognitive impairment ( MiniMental State Examination [ MMSE ] score &lt; =23 ) , history Diagnostic Statistical Manual Mental Disorders IV ( DSM IV ) diagnose major depression , unstable mild depression psychosis , participant take tolcapone exclude . ( Participants mild depression well control stable dose antidepressant medication least 4 week screen eligible . ) All participant severe ongoing unstable medical condition exclude include history poorly control diabetes , obesity associate metabolic syndrome , uncontrolled hypertension , cerebrovascular disease , form clinically significant cardiac disease , symptomatic orthostatic hypotension , renal failure , history abnormal renal function , seizure , alcohol/drug dependence , previous surgery Parkinson 's disease . Average daily consumption two 4oz ( 120 mL ) glass wine equivalent . Because know whether preladenant pass breast milk effect , , preladenant develop human unknown , woman breastfeed consider breastfeed exclude trial . Participants allergy/sensitivity study drug excipients . Participants clinically significant condition situation , condition study , opinion investigator , would interfere study evaluation optimal participation study . Participants use investigational drug within 30 day Screening . Participants participate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>